![Assay: Irreversible inhibition of rat brain cytosolic MAGL assessed as [3H] - EMBL-EBI](https://cedclinic.com/wp-content/uploads/2026/06/ced-pexels-4226264-1-150x150.jpg "Assay: Irreversible inhibition of rat brain cytosolic MAGL assessed as [3H] - EMBL-EBI 12")
Cannabis Users Spend Less Time in Epilepsy Monitoring Units—But the Reasons Are Unclear
Cannabis use was associated with a 0.9 day LOS reduction compared to non-users. Among patients admitted for spell classification, event capturability was 18.1% higher in cannabis users. Additionally, cannabis users had increased prevalence of…
Cannabidiol Cortical Effects: Clinical Trial Data
Clinical Takeaway CBD alone does not directly reduce brain electrical activity in the way traditional seizure medications do, based on testing in healthy adults. Its anti-seizure benefits in conditions like Dravet syndrome appear to come primarily from…
Cannabidiol Cortical Excitability Clinical Trial
Clinical Takeaway CBD did not directly reduce brain electrical excitability at doses up to 700 mg in healthy adults, suggesting its seizure-control benefits in approved conditions likely come from interactions with other anti-seizure medications rather…
Flourish + Live Well’s CBD Science Series CBD and Seizures in Dogs: What Science … – Instagram
✦ New CED Clinical Relevance #70Notable Clinical Interest Emerging findings or policy developments worth monitoring closely. ⚒ Cannabis News | CED Clinic EpilepsyCbdVeterinaryTranslational…
A desperate North Texas mom turned to CBD to stop her son’s seizures. She worries … – WFAA
✦ New CED Clinical Relevance #70Notable Clinical Interest Emerging findings or policy developments worth monitoring closely. ⚒ Cannabis News | CED Clinic Pediatric EpilepsyCbdSeizure…
Medical Cannabis Evidence Map: Broad Promise, Variable Proof
When considering only high-quality systematic reviews, as evaluated by the AMSTAR 2 tool, 42 out of 67 descriptions of treatment effects for up to 20 health outcomes were classified as 'Positive' or 'Potentially Positive.' These outcomes included pain,…
Cannabidiol & Cortical Excitability: Clinical Trial Results
Clinical Takeaway In a controlled crossover trial of healthy males, neither a low (30 mg) nor a high (700 mg) single dose of CBD produced measurable changes in cortical excitability compared to placebo. This suggests CBD may not have meaningful direct…
Cannabinoid Clinical Trials: CBD and Cortical Excitability
Clinical Takeaway In a controlled crossover trial of healthy men, neither a low (30 mg) nor a high (700 mg) single dose of CBD directly altered cortical excitability compared to placebo. This suggests that CBD’s well-documented seizure-reducing…
Cannabinoids in Pediatric Medicine: Evidence-Based Review
Clinical Takeaway Cannabinoids have been studied across a range of pediatric medical conditions, with evidence drawn from interventional trials, observational studies, and patient surveys. The current body of research supports cautious clinical…
Cannabidiol for Lennox-Gastaut: Cannabinoid Clinical Trials
Clinical Takeaway Plant-derived cannabidiol (CBD) oral solution produced meaningful reductions in drop seizures in patients with Lennox-Gastaut syndrome at thresholds below the traditional 50% benchmark used in clinical trials. Caregiver-reported…